In 2018, IDH2 was reported as a diagnostic and prognostic serum biomarker for NSCLC and high serum IDH2 levels appear to correlate with poor survival in patients with NSCLC [26]. This evidence concerns the gene IDH2 and non-small cell lung carcinoma.